Since strong evidence indicates that DAB2IP reactivation in prostate cancer counteracts metastasis and chemoresistance [15,16], we chose to edit PC3 and DU145 human prostate cancer cell lines; the two lines differ in DAB2IP expression levels, p53 status, and overall aggressiveness, rendering them suitable for exploring various mechanisms of DAB2IP regulation in cancer. This evidence concerns the gene TP53 and prostate cancer.